Fat Pill Clears Hurdle

Stocks are responding to the deal with Iran, as Orexigen clears safety hurdle for its obesity drug Contrave. Adam Feuerstein gives details.
Author:
Publish date:

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.